Marksans Pharma Limited (MARKSANS.BO)
Marksans Pharma Limited operates in the Drug Manufacturers - General industry of the Healthcare sector, headquartered in Mumbai, MA, IN. The stock last traded at $333.00, up 9.83% on the session, giving a market capitalisation of $150.93B. Its beta of 1.12 implies it has historically moved more than the broad market.
Marksans Pharma Limited, along with its associated entities, operates globally in the pharmaceutical sector, focusing on the entire lifecycle of generic medications, from their initial research and development to manufacturing, marketing, and ultimate sale. Its extensive product range addresses a wide spectrum of health conditions and therapeutic areas. These encompass pain management (analgesics, anti-inflammatory), diabetes, neurological disorders (epilepsy, neurology), cardiovascular health, hormonal treatments, oncology, gastrointestinal issues (gastroenterology, antacids, antiulceratives), benign prostatic hyperplasia, hyperparathyroidism, gynecology, antifungal and antibacterial applications, anti-allergy, vitamin supplements, dermatology, cephalosporins, and hypertension, also including injectable formulations. The company was established in 1992 and maintains its headquarters in Mumbai, India.
Marksans Pharma Limited is most often compared with the following Healthcare names: